---
schema_version: "secwatch.filing_event.v1"
accession: "0001854270-25-000062"
form_type: "8-K"
ticker: "SNTI"
cik: "0001854270"
company_name: "Senti Biosciences, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T14:02:34.971158+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Senti Bio reports Q1 2025 net loss $14.1M; SENTI-202 Phase 1 shows 4 of 7 cCR with MRD negativity

## Summary
- Net loss of $14.1M ($1.41 per share) for Q1 2025; cash and equivalents $33.8M as of March 31.
- Phase 1 SENTI-202 data: 4 of 7 patients achieved composite CR (3 CR, 1 CRh); all MRD negative by local standard of care.
- Preliminary RP2D set at 1.5 x 10^9 CAR NK cells given on Days 0,7,14 in 28-day cycles after lymphodepletion.
- Responses ongoing from 4+ to 8+ months; 3 patients received bone marrow transplant after SENTI-202.
- R&D expenses $9.3M (up $0.5M YoY); G&A expenses $7.1M (down $0.4M YoY).

## SEC filing metadata
- accession: 0001854270-25-000062
- form_type: 8-K
- ticker: SNTI
- cik: 0001854270
- company_name: Senti Biosciences, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1854270/000185427025000062/0001854270-25-000062-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1854270/000185427025000062/snti-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001854270-25-000062
- JSON: https://secwatch.observer/filing/0001854270-25-000062.json
- Plain text: https://secwatch.observer/filing/0001854270-25-000062.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.